phenylalanine has been researched along with Colitis, Mucous in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 48 (84.21) | 24.3611 |
| 2020's | 9 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Shah, ED | 1 |
| Boinpally, R; Breen-Lyles, M; Busciglio, I; Camilleri, M; Carrothers, TJ; Maselli, D; Muslin, A; Nord, SL; Vijayvargiya, P | 1 |
| Friedenberg, FK; Piech, G; Reichenbach, ZW; Selby, A | 1 |
| Brenner, DM; Sayuk, GS | 1 |
| Black, CJ; Ford, AC; Houghton, LA | 1 |
| Andrae, DA; Covington, PS; Dove, LS; Lembo, AJ | 1 |
| Brenner, DM; Cash, BD; Elmes, SJR; Gutman, CR; Jo, E; Liu, LWC; Sayuk, GS | 2 |
| Liu, R; Staller, K | 1 |
| Heidelbaugh, J; Jones, J; Kuritzky, L; Lacy, B; Lembo, A | 1 |
| Abel, JL; Brenner, DM; Burslem, K; Sayuk, GS | 1 |
| Andrae, DA; Chey, WD; Covington, PS; Dove, LS | 1 |
| Cash, BD; Chey, WD; Covington, PS; Dove, LS; Lacy, BE; Lembo, AJ | 1 |
| Keating, GM | 1 |
| Júdez, FJ; Vera, I | 1 |
| Bielefeldt, K; Gawron, AJ | 1 |
| Cash, BD; Covington, PS; Dove, LS; Lacy, BE; Schoenfeld, PS | 4 |
| Barkin, JS; Croteau, R | 1 |
| Özdener, AE; Rivkin, A | 1 |
| Camilleri, M; Chedid, V; Vijayvargiya, P | 1 |
| Barbara, G; Barbaro, MR; De Ponti, F; Dothel, G; Raschi, E | 1 |
| Chhaparia, A; Hammami, MB; Schroeder, K; Vareedayah, A | 1 |
| Abel, JL; Andrae, DA; Carson, RT | 1 |
| Chey, WD; Chuang, E; Earnest, DL; Olden, KW; Paul Nicandro, J; Shringarpure, R | 1 |
| Gunn, D; Major, GAD | 1 |
| Lai, SW | 1 |
| Almenoff, JS; Andrae, D; Covington, PS; Davenport, JM; Dove, LS; Fogel, R; Lembo, A; McIntyre, G; Randall, CW | 1 |
| Andrae, DA; Covington, PS; Patrick, DL | 1 |
| Traynor, K | 1 |
| Garnock-Jones, KP | 1 |
| Lembo, AJ; Nee, J; Zakari, M | 1 |
| Cash, BD; Earnest, DL; Lacy, BE; Rao, T | 1 |
| Lacy, BE | 1 |
| Andrae, DA; Covington, PS; Davenport, JM; Dove, LS; Lacy, BE; Lembo, AJ; Lopez, R; McIntyre, G; Schey, R; Turner, L; Zuckerman, MJ | 1 |
| Dickson, I | 1 |
| Rivkin, A; Rybalov, S | 1 |
| Storr, M | 1 |
| Frieling, T | 1 |
| Morgan, B | 1 |
| Abenavoli, L; Gasbarrini, A; Ianiro, G; Laterza, L; Scarpellini, E; Tack, J | 1 |
| Lacy, BE; Moreau, JC | 1 |
| Talley, NJ | 1 |
| Weber, HC | 1 |
| Cash, BD; Covington, PS; Dove, LS; Fant, RV; Henningfield, JE | 1 |
| Boeckxstaens, G; Camilleri, M | 1 |
| Corsetti, M; Whorwell, P | 1 |
| Camilleri, M | 2 |
| Bronner, J; Brown, PM; Cline, GA; Drossman, DA; Frazier, KS; Freiman, J; Gershon, MD; Jackson, JI; Sands, A; Wood, AJ; Zambrowicz, B | 1 |
| Boeckxstaens, G; Janssen, P; Tack, J; Wouters, M | 1 |
| Ervin, CM; Mangel, AW | 1 |
22 review(s) available for phenylalanine and Colitis, Mucous
| Article | Year |
|---|---|
Pathophysiology, Differential Diagnosis, and Treatment of Diabetic Diarrhea.
Topics: Antidiarrheals; Autonomic Nervous System Diseases; Blind Loop Syndrome; Celiac Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diarrhea; Diphenoxylate; Enteric Nervous System; Exocrine Pancreatic Insufficiency; Gastrointestinal Agents; Gastrointestinal Motility; Hypoglycemic Agents; Imidazoles; Inflammation; Inflammatory Bowel Diseases; Interstitial Cells of Cajal; Intestinal Absorption; Intestinal Mucosa; Irritable Bowel Syndrome; Loperamide; Neuroglia; Non-Nutritive Sweeteners; Oxidative Stress; Phenylalanine; Serotonin 5-HT3 Receptor Antagonists | 2019 |
Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Topics: Adult; Carbolines; Diarrhea; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine; Quality of Life; Rifaximin; United States; United States Food and Drug Administration | 2020 |
Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
Topics: Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Patient Selection; Phenylalanine | 2020 |
Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.
Topics: Adult; Constipation; Diarrhea; Double-Blind Method; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Male; Middle Aged; Phenylalanine; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Opioid, delta | 2017 |
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine; Quality of Life; Randomized Controlled Trials as Topic | 2017 |
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.
Topics: Clinical Trials as Topic; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine | 2017 |
Advancements in drug development for diarrhea-predominant irritable bowel syndrome.
Topics: Animals; Benzimidazoles; Diarrhea; Drug and Narcotic Control; Drug Design; Gastrointestinal Agents; Humans; Imidazoles; Internationality; Irritable Bowel Syndrome; Phenylalanine | 2018 |
Chronic diarrhoea in adults: what not to miss.
Topics: Adenocarcinoma; Adenoma; Antidiarrheals; Bile Acids and Salts; Celiac Disease; Chronic Disease; Colorectal Neoplasms; Diarrhea; Exocrine Pancreatic Insufficiency; Feces; Gastrointestinal Agents; Humans; Iatrogenic Disease; Imidazoles; Immunochemistry; Inflammatory Bowel Diseases; Irritable Bowel Syndrome; Leukocyte L1 Antigen Complex; Loperamide; Malabsorption Syndromes; Phenylalanine; Steatorrhea | 2019 |
Eluxadoline: First Global Approval.
Topics: Adult; Animals; Diarrhea; Drug Approval; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine; Receptors, Opioid, delta; Receptors, Opioid, mu | 2015 |
Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Topics: Antidepressive Agents, Tricyclic; Antidiarrheals; Carbolines; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Loperamide; Phenylalanine; Receptors, Opioid; Rifamycins; Rifaximin | 2015 |
Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Topics: Abdominal Pain; Anti-Bacterial Agents; Carbolines; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Narcotic Antagonists; Phenylalanine; Receptors, Opioid; Rifamycins; Rifaximin; Serotonin 5-HT3 Receptor Antagonists | 2016 |
Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Topics: Antidiarrheals; Carbolines; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Loperamide; Pancreatitis; Phenylalanine; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2016 |
Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Topics: Administration, Oral; Diarrhea; Disease Management; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine; Randomized Controlled Trials as Topic; Rifamycins; Rifaximin | 2016 |
[Therapy for irritable bowel syndrome in sight?].
Topics: Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Male; Phenylalanine | 2016 |
Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.
Topics: Abdominal Pain; Constipation; Diarrhea; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine; Receptors, Opioid | 2016 |
Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations.
Topics: Carbolines; Diarrhea; Disease Management; Humans; Imidazoles; Irritable Bowel Syndrome; Parasympatholytics; Phenylalanine; Rifamycins; Rifaximin; United States | 2016 |
New treatment options for irritable bowel syndrome with predominant diarrhea.
Topics: Anti-Bacterial Agents; Constipation; Diarrhea; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Narcotic Antagonists; Phenylalanine; Quality of Life; Receptors, Opioid; Rifamycins; Rifaximin | 2017 |
Dietary and pharmacological treatment of abdominal pain in IBS.
Topics: Abdominal Pain; Anti-Infective Agents; Antidepressive Agents; Butyrophenones; Dipeptides; GABA Agents; Gastrointestinal Agents; Histamine H1 Antagonists; Humans; Imidazoles; Irritable Bowel Syndrome; Mentha piperita; Parasympatholytics; Phenylalanine; Piperidines; Plant Oils; Probiotics; Quaternary Ammonium Compounds; Rifamycins; Rifaximin; Serotonin 5-HT3 Receptor Antagonists; Thiophenes; Visceral Pain | 2017 |
New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.
Topics: Animals; Gastrointestinal Agents; Humans; Imidazoles; Intestinal Mucosa; Intestines; Irritable Bowel Syndrome; Phenylalanine; Receptors, Opioid, delta; Receptors, Opioid, mu; Signal Transduction; Treatment Outcome | 2017 |
LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.
Topics: Animals; Biphenyl Compounds; Drugs, Investigational; Enzyme Inhibitors; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Phenylalanine; Serotonin Antagonists; Tryptophan Hydroxylase | 2010 |
LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin.
Topics: Animals; Biphenyl Compounds; Clinical Trials as Topic; Diarrhea; Double-Blind Method; Gastrointestinal Tract; Humans; Irritable Bowel Syndrome; Phenylalanine; Receptors, Serotonin; Serotonin; Tryptophan Hydroxylase | 2011 |
Clinical trials in irritable bowel syndrome: a review.
Topics: Alprostadil; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Carbolines; Dose-Response Relationship, Drug; Gastrointestinal Agents; Humans; Indoles; Irritable Bowel Syndrome; Lubiprostone; Peptides; Phenylalanine; Phloroglucinol; Randomized Controlled Trials as Topic; Rifamycins; Rifaximin | 2013 |
9 trial(s) available for phenylalanine and Colitis, Mucous
| Article | Year |
|---|---|
Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trials.
Topics: Abdominal Pain; Adult; Aged; Diarrhea; Double-Blind Method; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Male; Middle Aged; Phenylalanine; Treatment Outcome | 2020 |
Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.
Topics: Adult; Diarrhea; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Male; Middle Aged; Phenylalanine; Prognosis; Retrospective Studies; Time Factors | 2017 |
Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.
Topics: Abdominal Pain; Adult; Antidiarrheals; Diarrhea; Double-Blind Method; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Loperamide; Male; Middle Aged; Pain Measurement; Phenylalanine; Symptom Assessment | 2017 |
Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diarrhea; Double-Blind Method; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Loperamide; Male; Middle Aged; Phenylalanine; Prospective Studies | 2019 |
Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Topics: Adult; Diarrhea; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Male; Middle Aged; Phenylalanine; Receptors, Opioid, delta; Receptors, Opioid, mu; Treatment Outcome | 2013 |
Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
Topics: Abdominal Pain; Adult; Aged; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Irritable Bowel Syndrome; Male; Middle Aged; Pancreatitis; Phenylalanine | 2016 |
[A new remedy for diarrheal irritable bowel syndrome].
Topics: Diarrhea; Drug Approval; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine; United States | 2016 |
Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
Topics: Abdominal Pain; Adult; Aged; Constipation; Diarrhea; Double-Blind Method; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Male; Middle Aged; Nausea; Pancreatitis; Phenylalanine; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Spasm; Sphincter of Oddi Dysfunction | 2017 |
The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Biomarkers; Biphenyl Compounds; Constipation; Double-Blind Method; Feces; Female; Humans; Hydroxyindoleacetic Acid; Irritable Bowel Syndrome; Male; Middle Aged; Pain Measurement; Phenylalanine; Serotonin; Severity of Illness Index; Tryptophan Hydroxylase | 2011 |
26 other study(ies) available for phenylalanine and Colitis, Mucous
| Article | Year |
|---|---|
Delta Variant: Expanding the Indication for Eluxadoline to Bile Acid Diarrhea.
Topics: Bile Acids and Salts; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine | 2022 |
Safety and Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome-Diarrhea With or Without Bile Acid Diarrhea: Open-Label Study.
Topics: Adult; Bile Acids and Salts; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine; Quality of Life | 2022 |
Efficacy of Eluxadoline in Irritable Bowel Syndrome With Diarrhea.
Topics: Diarrhea; Humans; Imidazoles; Irritable Bowel Syndrome; Loperamide; Phenylalanine | 2020 |
Response to Black et al.
Topics: Diarrhea; Humans; Imidazoles; Irritable Bowel Syndrome; Loperamide; Phenylalanine | 2020 |
Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
Topics: Adult; Aged; Diarrhea; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine | 2021 |
Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide.
Topics: Absenteeism; Adolescent; Adult; Aged; Aged, 80 and over; Diarrhea; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Loperamide; Male; Middle Aged; Phenylalanine; Quality of Life; Surveys and Questionnaires; United States; Young Adult | 2021 |
In brief: Pancreatitis with eluxadoline (Viberzi) in patients without a gallbladder.
Topics: Cholecystectomy; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Pancreatitis; Phenylalanine; Risk Factors | 2017 |
Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.
Topics: Adult; Aged; Aged, 80 and over; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Agents; Humans; Imidazoles; Incidence; Irritable Bowel Syndrome; Male; Middle Aged; Pancreatitis; Phenylalanine; Product Surveillance, Postmarketing; Risk Assessment | 2018 |
Τ Eluxadoline for IBS-D.
Topics: Contraindications, Drug; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine | 2017 |
Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder.
Topics: Cholecystectomy; Gallbladder; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine; Treatment Outcome | 2017 |
Response to Croteau and Barkin.
Topics: Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine | 2017 |
Safety of Eluxadoline in Patients With Irritable Bowel Syndrome.
Topics: Diarrhea; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine | 2017 |
Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline.
Topics: Humans; Imidazoles; Irritable Bowel Syndrome; Pancreatitis; Phenylalanine | 2018 |
Eluxadoline-Associated Pancreatitis in a Post-Cholecystectomy Patient: A Case Report.
Topics: Adult; Cholecystectomy; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Pancreatitis; Phenylalanine | 2017 |
The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea.
Topics: Adult; Diarrhea; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Male; Middle Aged; Phenylalanine; Quality of Life; Surveys and Questionnaires | 2019 |
Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
Topics: Adult; Aged; Carbolines; Diarrhea; Female; Health Resources; Humans; Imidazoles; Irritable Bowel Syndrome; Middle Aged; Phenylalanine; Quality of Life; Rifaximin | 2019 |
Safety of Eluxadoline Use.
Topics: Diarrhea; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine | 2019 |
Response to Lai.
Topics: Diarrhea; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine | 2019 |
Item-level assessment of the irritable bowel syndrome quality of life questionnaire in patients with diarrheal irritable bowel syndrome.
Topics: Clinical Trials, Phase II as Topic; Diarrhea; Female; Humans; Imidazoles; Irritable Bowel Syndrome; Male; Models, Psychological; Phenylalanine; Psychometrics; Quality of Life; Surveys and Questionnaires | 2014 |
Eluxadoline approved for irritable bowel syndrome with diarrhea.
Topics: Constipation; Diarrhea; Drug Approval; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine; United States; United States Food and Drug Administration | 2015 |
Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
Topics: Administration, Oral; Adult; Diarrhea; Drug Approval; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine; Receptors, Opioid, mu; United States; United States Food and Drug Administration | 2016 |
IBS: Treating IBS with diarrhoea.
Topics: Diarrhea; Female; Humans; Imidazoles; Irritable Bowel Syndrome; Male; Phenylalanine | 2016 |
Drug development: A healthy pipeline.
Topics: Animals; Benzimidazoles; Benzofurans; Bile Acids and Salts; Carbolines; Colesevelam Hydrochloride; Colestipol; Disease Models, Animal; Enteric Nervous System; Female; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; Loperamide; Lubiprostone; Male; Mice; Natriuretic Peptides; Peptides; Phenylalanine; Receptors, Serotonin, 5-HT3; Receptors, Serotonin, 5-HT4; Rifamycins; Rifaximin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Visceral Pain | 2016 |
Board Review Vignette: Irritable Bowel Syndrome.
Topics: Abdominal Pain; Adult; Anion Exchange Resins; Antidiarrheals; Carbolines; Cholestyramine Resin; Constipation; Diarrhea; Disease Management; Female; Gastrointestinal Agents; Guanylyl Cyclase C Agonists; Humans; Imidazoles; Irritable Bowel Syndrome; Laxatives; Loperamide; Peptides; Phenylalanine; Probiotics; Rifamycins; Rifaximin; Selective Serotonin Reuptake Inhibitors | 2016 |
Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
Topics: Administration, Oral; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Double-Blind Method; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine; Placebos; Randomized Controlled Trials as Topic; Single-Blind Method; Substance-Related Disorders | 2017 |
Targeting serotonin synthesis to treat irritable bowel syndrome.
Topics: Biphenyl Compounds; Female; Humans; Hydroxyindoleacetic Acid; Irritable Bowel Syndrome; Male; Phenylalanine; Serotonin; Tryptophan Hydroxylase | 2011 |